Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...
Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...
Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked ...
The trial, which was funded by the drugs’ maker Eli Lilly, found that most ... to discontinue the drugs when their weight ...
Meanwhile, supply shortages of weight-loss drugs like Zepbound and Ozempic have led to a surge in knockoff "compounder" drugs ...
In essence, Viking could be in the early stages of developing a quadruple-pathway weight loss drug featuring the ... just yet ...
The FDA became aware of the problem after a patient submitted a complaint to the regulator that a vial of semaglutide from ...
US drug shortages have decreased from 323 to 277 as of September 2024, yet many essential drugs remain scarce, with 50% of ...
Eli Lilly's ... weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from widespread ...